Drug prevents bone loss in prostate cancer: Amgen (Reuters)Reuters - In a study, Amgen Inc's
experimental drug denosumab reduced the risk of osteoporosis
and fracture in men being treated with prostate cancer
medicines that can cause bone loss, the company said on Monday.
http://us.rd.yahoo.com/health/news/rss/search/*http://health.yahoo.com/news/reuters/amgen_denosumab_dc.html